We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aduro Reports Partial Hold Lift on LADD Studies in U.S.
Read MoreHide Full Article
Aduro Biotech, Inc. received encouraging news when the FDA lifted the partial clinical hold on studies evaluating investigational agents based on its LADD (live, attenuated double-deleted) immunotherapy platform. With the partial hold lift, the company has now been able to resume patient enrollment in all Aduro-sponsored studies.
However, the company has had to revise and implement study protocols in accordance with the FDA’s guideline in order to recommence enrollment. These guidelines include extended patient surveillance, exclusion of patients with certain prosthetic devices that are not easily removed, and guidance in the administration of prophylactic antibiotics following LADD-based treatment in patients who may receive immune-suppressive treatments.
In its press release, Aduro stated that it is on track to initiate a phase II study utilizing the LADD-based therapy CRS-207, in combination with an anti-PD-1 compound, for the treatment of mesothelioma in the first half of 2017.
We remind investors that last month, the FDA had placed a partial clinical hold on studies evaluating Aduro’s LADD-based agents, bringing patient enrollment to a halt. The decision came after a blood culture sample taken from an indwelling port of a metastatic pancreatic cancer patient tested positive for Listeria.
Note that Aduro is developing the LADD platform for the treatment of multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. In addition, a personalized form of LADD is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor.
Several studies utilizing this platform are being conducted, which include a phase I/II study on CRS-207, in combination with Incyte Corporation’s (INCY - Free Report) selective IDO1 inhibitor epacadostat, for the treatment of ovarian cancer; and a phase I lung cancer study on ADU-214, in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech among others.
Meanwhile, Aduro continues to progress with its two other platform technologies – the STING pathway activator and the B-select antibody programs.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016 while earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged 85% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Aduro Reports Partial Hold Lift on LADD Studies in U.S.
Aduro Biotech, Inc. received encouraging news when the FDA lifted the partial clinical hold on studies evaluating investigational agents based on its LADD (live, attenuated double-deleted) immunotherapy platform. With the partial hold lift, the company has now been able to resume patient enrollment in all Aduro-sponsored studies.
However, the company has had to revise and implement study protocols in accordance with the FDA’s guideline in order to recommence enrollment. These guidelines include extended patient surveillance, exclusion of patients with certain prosthetic devices that are not easily removed, and guidance in the administration of prophylactic antibiotics following LADD-based treatment in patients who may receive immune-suppressive treatments.
In its press release, Aduro stated that it is on track to initiate a phase II study utilizing the LADD-based therapy CRS-207, in combination with an anti-PD-1 compound, for the treatment of mesothelioma in the first half of 2017.
We remind investors that last month, the FDA had placed a partial clinical hold on studies evaluating Aduro’s LADD-based agents, bringing patient enrollment to a halt. The decision came after a blood culture sample taken from an indwelling port of a metastatic pancreatic cancer patient tested positive for Listeria.
ADURO BIOTECH Price
ADURO BIOTECH Price | ADURO BIOTECH Quote
Note that Aduro is developing the LADD platform for the treatment of multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. In addition, a personalized form of LADD is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor.
Several studies utilizing this platform are being conducted, which include a phase I/II study on CRS-207, in combination with Incyte Corporation’s (INCY - Free Report) selective IDO1 inhibitor epacadostat, for the treatment of ovarian cancer; and a phase I lung cancer study on ADU-214, in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech among others.
Meanwhile, Aduro continues to progress with its two other platform technologies – the STING pathway activator and the B-select antibody programs.
Aduro currently has a Zacks Rank #2 (Buy).
Another Stock to Consider
Vanda Pharmaceuticals, Inc. (VNDA - Free Report) is another favorably placed stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016 while earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged 85% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>